{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:50:08Z","timestamp":1794329408436,"version":"4.9.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clinthera.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:48:50Z","timestamp":1721177330000},"page":"612-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer"],"prefix":"10.1016","volume":"46","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Graybill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Churruca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja \u00d8r","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oi Wah Stephanie","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Baurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Denys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad","family":"Ghamande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Ioana","family":"Braicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amnon","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Prendergast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekemi","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Kheibarshekan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.06.001_bib0001","doi-asserted-by":"crossref","first-page":"7170","DOI":"10.1021\/jm901188v","article-title":"Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors","volume":"52","author":"Jones","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0002","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0003","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0004","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0005","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00280-019-03774-w","article-title":"Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer","volume":"83","author":"Moore","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0006","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","article-title":"Efficacy and safety of niraparib as maintenance treatment in older patients (\u226570 years) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial","volume":"152","author":"Fabbro","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0008","unstructured":"ZEJULA (niraparib) capsules for oral use: prescribing information. Available at: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Zejula_Capsules\/pdf\/ZEJULA-CAPSULES-PI-PIL.PDF [Accessed May 09, 2023]."},{"key":"10.1016\/j.clinthera.2024.06.001_bib0009","unstructured":"Zejula 100 mg hard capsules: summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/documents\/product-information\/zejula-epar-product-information_en.pdf [Accessed May 09, 2023]."},{"key":"10.1016\/j.clinthera.2024.06.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.04.024","article-title":"Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer","volume":"189","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0011","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","article-title":"The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial","volume":"14","author":"Sandhu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0012","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/cncr.34706","article-title":"Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"129","author":"Mirza","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","article-title":"Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients","volume":"81","author":"van Andel","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0015","unstructured":"Zejula Assessment Report. EMA\/294945\/2022. European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/zejula-h-c-004249-x-0029-epar-assessment-report-variation_en.pdf [Accessed May 09, 2023]."},{"key":"10.1016\/j.clinthera.2024.06.001_bib0016","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s10637-017-0451-2","article-title":"Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer","volume":"35","author":"van Andel","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0017","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03891.x","article-title":"Interpreting population pharmacokinetic-pharmacodynamic analyses \u2013 a clinical viewpoint","volume":"71","author":"Duffull","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0018","unstructured":"United States Food and Drug Administration: Guidance for Industry. Population pharmacokinetics. 1999. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/population-pharmacokinetics [Accessed November 14, 2018]."},{"key":"10.1016\/j.clinthera.2024.06.001_bib0019","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0020","doi-asserted-by":"crossref","first-page":"viii335","DOI":"10.1093\/annonc\/mdy285.150","article-title":"A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight (wt) and platelet (blplt) count: blinded pooled interim analysis of safety data from the PRIMA study","volume":"29","author":"Gonzalez","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0021","unstructured":"European Medicines Agency: Committee or Medicinal Products for Human Use. Guideline on reporting the results of population pharmacokinetic analyses. London, 2007. Available at: https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-reporting-results-population-pharmacokinetic-analyses_en.pdf [Accessed August 29, 2020]."},{"key":"10.1016\/j.clinthera.2024.06.001_bib0022","unstructured":"United States Food and Drug Administration: Guidance for Industry. Exposure-response relationships\u2014study design, data analysis, and regulatory applications. 2003. https:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm072109.pdf [Accessed August 8, 2020]."},{"key":"10.1016\/j.clinthera.2024.06.001_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchromb.2016.11.020","article-title":"Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine","volume":"1040","author":"van Andel","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0024","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0026","series-title":"Modern Applied Statistics with S","author":"Venables","year":"2002"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0027","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0028","article-title":"Modeling and impact of organ function on the population pharmacokinetics (PK) of niraparib, a selective poly (ADP-Ribose) polymerase (PARP)-1 and -2 inhibitor","volume":"28(suppl 5):V344","author":"Zhang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0029","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1200\/JCO.21.00471","article-title":"Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update","volume":"39","author":"Griggs","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0030","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2016.69.1899","article-title":"How to manage the obese patient with cancer","volume":"34","author":"Renehan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2024.06.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231173183","article-title":"The role of PARP inhibitor combination therapy in ovarian cancer","volume":"15","author":"Hockings","year":"2023","journal-title":"Ther Adv Med Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824001395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T15:32:58Z","timestamp":1728142378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824001395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0149291824001395"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}